These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 11901091)

  • 1. Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles.
    Tracy TS; Hutzler JM; Haining RL; Rettie AE; Hummel MA; Dickmann LJ
    Drug Metab Dispos; 2002 Apr; 30(4):385-90. PubMed ID: 11901091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dapsone activation of CYP2C9-mediated metabolism: evidence for activation of multiple substrates and a two-site model.
    Hutzler JM; Hauer MJ; Tracy TS
    Drug Metab Dispos; 2001 Jul; 29(7):1029-34. PubMed ID: 11408370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzymatic determinants of the substrate specificity of CYP2C9: role of B'-C loop residues in providing the pi-stacking anchor site for warfarin binding.
    Haining RL; Jones JP; Henne KR; Fisher MB; Koop DR; Trager WF; Rettie AE
    Biochemistry; 1999 Mar; 38(11):3285-92. PubMed ID: 10079071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes.
    Yamazaki H; Inoue K; Chiba K; Ozawa N; Kawai T; Suzuki Y; Goldstein JA; Guengerich FP; Shimada T
    Biochem Pharmacol; 1998 Jul; 56(2):243-51. PubMed ID: 9698079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential activation of CYP2C9 variants by dapsone.
    Hummel MA; Dickmann LJ; Rettie AE; Haining RL; Tracy TS
    Biochem Pharmacol; 2004 May; 67(10):1831-41. PubMed ID: 15130760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites.
    Korzekwa KR; Krishnamachary N; Shou M; Ogai A; Parise RA; Rettie AE; Gonzalez FJ; Tracy TS
    Biochemistry; 1998 Mar; 37(12):4137-47. PubMed ID: 9521735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amiodarone analog-dependent effects on CYP2C9-mediated metabolism and kinetic profiles.
    Kumar V; Locuson CW; Sham YY; Tracy TS
    Drug Metab Dispos; 2006 Oct; 34(10):1688-96. PubMed ID: 16815961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates.
    Takanashi K; Tainaka H; Kobayashi K; Yasumori T; Hosakawa M; Chiba K
    Pharmacogenetics; 2000 Mar; 10(2):95-104. PubMed ID: 10761997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms.
    Haining RL; Hunter AP; Veronese ME; Trager WF; Rettie AE
    Arch Biochem Biophys; 1996 Sep; 333(2):447-58. PubMed ID: 8809086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The molecular basis of dapsone activation of CYP2C9-catalyzed nonsteroidal anti-inflammatory drug oxidation.
    Nair PC; Burns K; Chau N; McKinnon RA; Miners JO
    J Biol Chem; 2023 Dec; 299(12):105368. PubMed ID: 37866634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis.
    Ieiri I; Tainaka H; Morita T; Hadama A; Mamiya K; Hayashibara M; Ninomiya H; Ohmori S; Kitada M; Tashiro N; Higuchi S; Otsubo K
    Ther Drug Monit; 2000 Jun; 22(3):237-44. PubMed ID: 10850388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of CYP2C9-mediated metabolism by a series of dapsone analogs: kinetics and structural requirements.
    Hutzler JM; Kolwankar D; Hummel MA; Tracy TS
    Drug Metab Dispos; 2002 Nov; 30(11):1194-200. PubMed ID: 12386124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies of flurbiprofen 4'-hydroxylation. Additional evidence suggesting the sole involvement of cytochrome P450 2C9.
    Tracy TS; Marra C; Wrighton SA; Gonzalez FJ; Korzekwa KR
    Biochem Pharmacol; 1996 Oct; 52(8):1305-9. PubMed ID: 8937439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9*3 allele.
    Shimamoto J; Ieiri I; Urae A; Kimura M; Irie S; Kubota T; Chiba K; Ishizaki T; Otsubo K; Higuchi S
    Eur J Clin Pharmacol; 2000 Apr; 56(1):65-8. PubMed ID: 10853880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.
    Lasker JM; Wester MR; Aramsombatdee E; Raucy JL
    Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes.
    Takahashi H; Kashima T; Nomoto S; Iwade K; Tainaka H; Shimizu T; Nomizo Y; Muramoto N; Kimura S; Echizen H
    Pharmacogenetics; 1998 Oct; 8(5):365-73. PubMed ID: 9825828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of CYP2C9 genetic polymorphism on the metabolism of flurbiprofen in vitro.
    Wang L; Bao SH; Pan PP; Xia MM; Chen MC; Liang BQ; Dai DP; Cai JP; Hu GX
    Drug Dev Ind Pharm; 2015; 41(8):1363-7. PubMed ID: 25144335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement.
    van der Weide J; Steijns LS; van Weelden MJ; de Haan K
    Pharmacogenetics; 2001 Jun; 11(4):287-91. PubMed ID: 11434505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphic variants of CYP2C9: mechanisms involved in reduced catalytic activity.
    Wei L; Locuson CW; Tracy TS
    Mol Pharmacol; 2007 Nov; 72(5):1280-8. PubMed ID: 17686967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP2C9*3 influences the metabolism and the drug-interaction of candesartan in vitro.
    Hanatani T; Fukuda T; Ikeda M; Imaoka S; Hiroi T; Funae Y; Azuma J
    Pharmacogenomics J; 2001; 1(4):288-92. PubMed ID: 11908770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.